Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMB NYSE:BHG NASDAQ:IPHA NASDAQ:IRWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$24.70-3.1%$20.80$7.75▼$27.17$189.51M0.67157,119 shs122,376 shsBHGBright Health Group$6.56+0.6%$6.76$4.94▼$82.40$52.36M0.9372,717 shs5,796 shsIPHAInnate Pharma$2.13+1.7%$2.00$1.29▼$3.51$199.13M0.226,354 shs1,849 shsIRWDIronwood Pharmaceuticals$1.32$0.90$0.53▼$5.21$214.41M0.321.46 million shs548,103 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences0.00%-8.28%+34.24%+60.39%+51.91%BHGBright Health Group0.00%+0.79%-3.17%-4.51%+30.68%IPHAInnate Pharma0.00%-5.56%-1.16%-0.75%-7.41%IRWDIronwood Pharmaceuticals0.00%+3.94%+71.12%+112.90%-73.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASMBAssembly Biosciences3.8894 of 5 stars3.44.00.04.72.70.00.0BHGBright Health GroupN/AN/AN/AN/AN/AN/AN/AN/AIPHAInnate Pharma2.2175 of 5 stars3.72.00.00.02.71.70.0IRWDIronwood Pharmaceuticals4.6935 of 5 stars3.15.00.03.42.70.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.75Moderate Buy$38.6756.55% UpsideBHGBright Health Group 0.00N/AN/AN/AIPHAInnate Pharma 3.33Buy$11.00417.65% UpsideIRWDIronwood Pharmaceuticals 2.14Hold$4.94274.24% UpsideCurrent Analyst Ratings BreakdownLatest BHG, IPHA, IRWD, and ASMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025ASMBAssembly BiosciencesZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/18/2025ASMBAssembly BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.007/28/2025IPHAInnate PharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$28.52M6.64N/AN/A$5.25 per share4.70BHGBright Health Group$2.76B0.02N/AN/A($25.47) per share-0.26IPHAInnate Pharma$21.77M9.00N/AN/A$0.11 per share19.32IRWDIronwood Pharmaceuticals$351.41M0.61$0.05 per share26.69($1.88) per share-0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$40.18M-$5.58N/AN/AN/A-117.20%-149.01%-39.04%11/6/2025 (Estimated)BHGBright Health Group-$1.46B-$208.73N/AN/AN/A-85.40%N/A-10.26%N/AIPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)IRWDIronwood Pharmaceuticals$880K-$0.05N/A5.28N/A-2.25%-2.46%2.19%11/6/2025 (Estimated)Latest BHG, IPHA, IRWD, and ASMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025IRWDIronwood Pharmaceuticals-$0.02$0.14+$0.16$0.14$62.02 million$85.24 million8/6/2025Q2 2025ASMBAssembly Biosciences-$1.73-$1.33+$0.40-$1.33$5.30 million$9.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ABHGBright Health GroupN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A1.641.64BHGBright Health GroupN/A1.041.04IPHAInnate Pharma2.522.602.60IRWDIronwood PharmaceuticalsN/A0.820.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%BHGBright Health GroupN/AIPHAInnate Pharma0.16%IRWDIronwood PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.10%BHGBright Health Group58.40%IPHAInnate Pharma31.89%IRWDIronwood Pharmaceuticals12.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.67 million7.28 millionOptionableBHGBright Health Group2,8407.98 million3.32 millionNot OptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableIRWDIronwood Pharmaceuticals220162.43 million141.81 millionOptionableBHG, IPHA, IRWD, and ASMB HeadlinesRecent News About These CompaniesCharles Schwab Investment Management Inc. Buys 663,775 Shares of Ironwood Pharmaceuticals, Inc. $IRWDAugust 31 at 3:08 AM | marketbeat.comVanguard Group Inc. Sells 3,842,394 Shares of Ironwood Pharmaceuticals, Inc. $IRWDAugust 31 at 3:07 AM | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Grows Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)August 16, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Recommendation of "Hold" by AnalystsAugust 15, 2025 | marketbeat.comLeerink Partnrs Issues Negative Forecast for IRWD EarningsAugust 11, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Upgraded to Strong-Buy at Wall Street ZenAugust 10, 2025 | marketbeat.comFY2027 Earnings Estimate for IRWD Issued By Zacks ResearchAugust 9, 2025 | marketbeat.comIronwood (IRWD) Q2 EPS Jumps 600%August 8, 2025 | theglobeandmail.comIRWD Stock Rises as Q2 Earnings & Revenues Trump EstimatesAugust 8, 2025 | zacks.comIronwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue EstimatesAugust 7, 2025 | zacks.comIronwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 ...August 7, 2025 | gurufocus.comIronwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 ...August 7, 2025 | gurufocus.comIronwood Pharmaceuticals Q2 2025 Earnings: EPS of $0.15 and Revenue of $85.24M Surpass EstimatesAugust 7, 2025 | gurufocus.comIronwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial GuidanceAugust 7, 2025 | businesswire.comIronwood Pharmaceuticals (IRWD) Projected to Post Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Purchased by Federated Hermes Inc.August 6, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Holdings Increased by XTX Topco LtdAugust 4, 2025 | marketbeat.comBank of New York Mellon Corp Sells 478,522 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)August 3, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Acquired by GSA Capital Partners LLPAugust 2, 2025 | marketbeat.comVanguard Group Inc. Expands Stake in Ironwood PharmaceuticalsJuly 10, 2025 | gurufocus.comWhy Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?June 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHG, IPHA, IRWD, and ASMB Company DescriptionsAssembly Biosciences NASDAQ:ASMB$24.70 -0.80 (-3.14%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$24.73 +0.03 (+0.12%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Bright Health Group NYSE:BHG$6.56 +0.04 (+0.61%) As of 08/29/2025Bright Health Group, Inc., a healthcare company, provides health insurance policies in the United States. It operates in two segments, Bright HealthCare and Consumer Care. The Consumer Care segment delivers virtual and in-person clinical care services contracts through primary care clinics. It operates managed and affiliated risk-bearing clinics within its integrated care delivery system, which included embedded pharmacy, laboratory, radiology, and population health focused specialty services. The Bright HealthCare segment offers medicare health plan products to consumers. The company was formerly known as Bright Health Inc. and changed its name to Bright Health Group, Inc. in February 2021. Bright Health Group, Inc. was incorporated in 2015 and is headquartered in Minneapolis, Minnesota.Innate Pharma NASDAQ:IPHA$2.12 +0.04 (+1.67%) As of 08/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Ironwood Pharmaceuticals NASDAQ:IRWD$1.32 0.00 (0.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.32 +0.00 (+0.38%) As of 08/29/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
